NeuroWave CE marks brain monitor for anaesthetised patients
This article was originally published in Clinica
Start-up company NeuroWave Systems has CE marked its lead product, the NeuroSense brain monitor, for sale in Europe. The device measures the brain function of patients undergoing general anaesthesia or sedation, which could improve patient outcomes and safety, the firm believes. For example, anaesthesia can increase the risk of stroke, which can be detected by the monitor. NeuroSense measures electroencephalogram (EEG) signals from both hemispheres of the brain, providing real-time feedback. NeuroWave (Cleveland Heights, Ohio) hopes that brain function monitoring during anaesthesia will become the standard of care in future, and is also pursuing US FDA approval. The market is currently worth $1bn per year and growing, it estimated.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.